...
首页> 外文期刊>Glycobiology. >The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo
【24h】

The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo

机译:NEU1选择性唾液酸酶抑制剂C9-丁基酰胺-DANA可以在人肺和鼠肺体内阻断唾液酸酶活性和NEU1介导的生物活性

获取原文
获取原文并翻译 | 示例

摘要

Neuraminidase-1 ( NEU1) is the predominant sialidase expressed in human airway epithelia and lung microvascular endothelia where it mediates multiple biological processes. We tested whether the NEU1-selective sialidase inhibitor, C9-butyl-amide-2-deoxy-2,3-dehydro-N-acetylneuraminic acid ( C9-BA-DANA), inhibits one or more established NEU1-mediated bioactivities in human lung cells. We established the IC50 values of C9-BA-DANA for total sialidase activity in human airway epithelia, lung microvascular endothelia and lung fibroblasts to be 3.74 mu M, 13.0 mu M and 4.82 mu M, respectively. In human airway epithelia, C9-BA-DANA dose-dependently inhibited flagellin-induced, NEU1-mediated mucin-1 ectodomain desialylation, adhesiveness for Pseudomonas aeruginosa and shedding. In lung microvascular endothelia, C9-BA-DANA reversed NEU1-driven restraint of cell migration into a wound and disruption of capillary-like tube formation. NEU1 and its chaperone/transport protein, protective protein/cathepsin A ( PPCA), were differentially expressed in these same cells. Normalized NEU1 protein expression correlated with total sialidase activity whereas PPCA expression did not. In contrast to eukaryotic sialidases, C9-BA-DANA exerted far less inhibitory activity for three selected bacterial neuraminidases ( IC50 > 800 mu M). Structural modeling of the four human sialidases and three bacterial neuraminidases revealed a loop between the seventh and eighth strands of the beta-propeller fold, that in NEU1, was substantially shorter than that seen in the six other enzymes. Predicted steric hindrance between this loop and C9-BA-DANA could explain its selectivity for NEU1. Finally, pretreatment of mice with C9-BA-DANA completely protected against flagellin-induced increases in lung sialidase activity. Our combined data indicate that C9-BA-DANA inhibits endogenous and ectopically expressed sialidase activity and established NEU1-mediated bioactivities in human airway epithelia, lung microvascular endothelia, and fibroblasts in vitro and murine lungs in vivo.
机译:Neuraminidase-1(NEU1)是在人气道上皮和肺微血管内皮中表达的主要唾液酸酶,介导多种生物学过程。我们测试了NEU1选择性唾液酸酶抑制剂C9-丁基酰胺-2-脱氧-2,3-脱氢-N-乙酰神经氨酸(C9-BA-DANA)是否抑制人肺中一种或多种既定的NEU1介导的生物活性细胞。我们确定了C9-BA-DANA的总唾液酸酶活性在人气道上皮细胞,肺微血管内皮细胞和肺成纤维细胞中的IC50值分别为3.74μM,13.0μM和4.82μM。在人的气道上皮细胞中,C9-BA-DANA剂量依赖性地抑制鞭毛蛋白诱导的NEU1介导的mucin-1胞外域脱唾液酸化,铜绿假单胞菌的粘附性和脱落。在肺微血管内皮细胞中,C9-BA-DANA逆转了NEU1驱动的细胞向伤口迁移的抑制,并破坏了毛细管样管的形成。 NEU1及其伴侣/转运蛋白,保护性蛋白/组织蛋白酶A(PPCA)在这些相同细胞中差异表达。标准化的NEU1蛋白表达与总唾液酸酶活性相关,而PPCA表达则不相关。与真核唾液酸酶相反,C9-BA-DANA对三种选定的细菌神经氨酸酶(IC50> 800μM)的抑制活性要低得多。对四个人类唾液酸酶和三个细菌神经氨酸酶的结构模型显示,β-螺旋桨折叠的第七和第八链之间存在一个环,在NEU1中该环比在其他六个酶中所见的短得多。 C9-BA-DANA与该环之间的空间位阻可以解释其对NEU1的选择性。最后,用C9-BA-DANA预处理小鼠可完全防御鞭毛蛋白诱导的肺唾液酸酶活性增加。我们的综合数据表明,C9-BA-DANA抑制内源性和异位表达的唾液酸酶活性,并在体外和鼠肺中在人气道上皮,肺微血管内皮和成纤维细胞中建立了NEU1介导的生物活性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号